Emerging Alzheimer's disease treatment paradigms: A late-stage clinical trial review.

ABSTRACT:

Introduction

Without disease-modifying interventions, Medicare and Medicaid spending on Alzheimer's disease (AD) management is expected to reach 637 billion USD annually by 2050. The recent advent of promising AD therapies after decades of a near-total failure rate in clinical trials suggests that more disease-modifying therapies are on the horizon. In this review, we assess the late-stage pipeline of disease-modifying candidates for AD and offer a novel classification of intervention candidates by treatment paradigms-groups of candidates that share an underlying biological mechanism of action and general disease target.

Methods

We extracted data from the National Library of Medicine clinical trials database regarding Phase 2 and 3 trials of disease-modifying AD therapies. W

SUBMITTER: Hlavka JP 

PROVIDER: S-EPMC11694526 | biostudies-literature | 2024 Oct-Dec

REPOSITORIES: biostudies-literature